retatrutide south africa Obesity is expected to affect nearly a quarter of the world population by 2035. Retatrutide, an investigational GIP, GLP-1, and GCG receptor agonist, holds promise for weight reduction in adults. New CURATED Size:.5 ounce 🚨 TRIUMPH-1: #retatrutide topline

retatrutide south africa Obesity is expected to affect nearly a quarter of the world population by 2035. Retatrutide, an investigational GIP, GLP-1, and GCG receptor agonist, holds promise for weight reduction in adults. New CURATED Size:.5 ounce 🚨 TRIUMPH-1: #retatrutide topline

🚨 TRIUMPH-1: #retatrutide topline data🚨 Phase 3, n=2,339, 80 wk, obesity without diabetes (efficacy estimand): 🔹 12 mg: -28.3% body weight (-31.9 kg) 🔸 9 mg: -25.9% | 4 mg: -19.0%

Less common but more serious risks include infection, bleeding, fluid collections, contour irregularities, or anesthesia complications

CURATED

Size:.5 ounce

Diabetes, post-viral illness, prior surgeries, motility-slowing medications, and autoimmune or neurological conditions are all known triggers